All Releases
 |
VIA Pharmaceuticals Set to Join Russell Microcap Index
Jun 27, 2008
|
10.7 KB |
|
| |
SAN FRANCISCO, June 27, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, will join the Russell Microcap Index when Russell Investments reconstitutes its family of U.S. indexes on June 27 after ...
|
|
VIA Pharmaceuticals to Present at Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
Jun 3, 2008
|
6.7 KB |
|
| |
SAN FRANCISCO, June 3, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that Lawrence K. Cohen, PhD, president and chief executive officer of VIA, and James G. Stewart, senior vice pr...
|
|
VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
May 15, 2008
|
11.2 KB |
|
| |
SAN FRANCISCO, May 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it has completed patient enrollment in its acute coronary syndrome (ACS) study. The ACS study is one...
|
|
VIA Pharmaceuticals to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
May 8, 2008
|
7.0 KB |
|
| |
SAN FRANCISCO, May 8, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that James G. Stewart, senior vice president and chief financial officer, will present a company update at the R...
|
|
VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
Apr 4, 2008
|
10.5 KB |
|
| |
SAN FRANCISCO, April 4, 2008, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that the independent Data Safety Monitoring Board (DSMB) for its VIA-2291 Phase 2 clinical trial program...
|
|
VIA Pharmaceuticals Complies With NASDAQ Rule
Mar 28, 2008
|
9.2 KB |
|
| |
SAN FRANCISCO, March 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today, in compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), that the independent audit report included i...
|
|
VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
Mar 20, 2008
|
11.7 KB |
|
| |
SAN FRANCISCO, March 20, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it has completed patient enrollment in its carotid endarterectomy (CEA) study, the first of three Phase ...
|
|
VIA Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
Mar 11, 2008
|
6.7 KB |
|
| |
SAN FRANCISCO, March 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that Lawrence Cohen PhD, chief executive officer, and James G. Stewart, senior vice president and chief finan...
|
|
VIA Pharmaceuticals to Present at Susquehanna and Rodman & Renshaw Conferences on March 4, 2008
Feb 26, 2008
|
6.8 KB |
|
| |
SAN FRANCISCO, Feb 26, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that James G. Stewart, senior vice president, chief financial officer of VIA, will present a company upda...
|
|
VIA Pharmaceuticals to Present at BIO CEO & Investment Conference
Feb 6, 2008
|
6.6 KB |
|
| |
SAN FRANCISCO, Feb 06, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that Lawrence K. Cohen Ph.D., chief executive officer of VIA, will present a company update at the 2008 BIO CEO...
|
|
VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
Jan 16, 2008
|
10.5 KB |
|
| |
SAN FRANCISCO, Jan 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that Rebecca A. Taub, M.D. has joined VIA as senior vice president of research and development. Dr. Taub brings...
|
|
VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
Jan 7, 2008
|
13.0 KB |
|
| |
SAN FRANCISCO, Jan 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it has enrolled the first patient in its Phase 2 clinical trial that utilizes Positron Emission Tomography...
|
|
VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
Nov 12, 2007
|
9.8 KB |
|
| |
SAN FRANCISCO, Nov 12, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, today announced the expansion of its clinical advisory board. Joining the clinical advisory board's chair, Marc Pfeffer, M.D., ...
|
|
VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis
Nov 6, 2007
|
10.5 KB |
|
| |
SAN FRANCISCO and ORLANDO, Fla., Nov 06, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, today presented data showing that VIA-2291 significantly inhibited vascular inflammation in a mouse model of ...
|
|
VIA Pharmaceuticals Announces Participation in Three Healthcare Investor Conferences in November
Nov 1, 2007
|
6.9 KB |
|
| |
SAN FRANCISCO, Nov 01, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biopharmaceutical company focused on the development of compounds for the treatment of cardiovascular disease, today announced that Larry Cohen, Ph.D., president and CEO of VIA, will present at three upcoming conferences in Nove...
|
|
VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
Oct 25, 2007
|
10.8 KB |
|
| |
SAN FRANCISCO, Oct 25, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it will soon initiate a third Phase II clinical trial for VIA-2291, its lead compound. VIA-2291 targets in...
|
|
VIA Pharmaceuticals' Lead Compound, VIA-2291, Chosen as a Top Ten Most Licensable Cardiovascular Program for Windhover Information's Therapeutic Area Partnerships Conference
Oct 19, 2007
|
9.9 KB |
|
| |
SAN FRANCISCO, Oct 19, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals (Nasdaq: VIAP) a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that Windhover Information has chosen the company's lead compound, VIA-2291, as one of the top ten most interest...
|
|
VIA Pharmaceuticals Announces Positive DSMB Recommendation for VIA-2291 Clinical Trials
Oct 10, 2007
|
9.3 KB |
|
| |
SAN FRANCISCO, Oct 10, 2007 (BUSINESS WIRE) -- VIA Pharmaceuticals (NASDAQ: VIAP) a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that its independent Data Safety Monitoring Board (DSMB) for its two VIA-2291 Phase II clinical trials recently met to review patient safety an...
|
|
VIA Pharmaceuticals Announces Funding for Pharmacogenomic Sub-Study on VIA-2291 ACS Trial
Oct 3, 2007
|
9.9 KB |
|
| |
SAN FRANCISCO, Oct 03, 2007 (BUSINESS WIRE) -- VIA Pharmaceuticals (NASDAQ: VIAP) a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, today announced funding of a research initiative for a pharmacogenomics sub-study in its VIA-2291 Acute Coronary Syndrome (ACS) trial. This study will be funde...
|
|
VIA Pharmaceuticals to Present at the 2007 BIO Investor Forum
Oct 1, 2007
|
6.6 KB |
|
| |
SAN FRANCISCO, Oct 01, 2007 (BUSINESS WIRE) -- VIA Pharmaceuticals (NASDAQ: VIAP) a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, today announced that Lawrence Cohen PhD, chief executive officer of VIA, will present a company update at the 2007 BIO Investor Forum in San Francisco on Thurs...
|
|
|
